BR112022005995A2 - Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas - Google Patents

Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas

Info

Publication number
BR112022005995A2
BR112022005995A2 BR112022005995A BR112022005995A BR112022005995A2 BR 112022005995 A2 BR112022005995 A2 BR 112022005995A2 BR 112022005995 A BR112022005995 A BR 112022005995A BR 112022005995 A BR112022005995 A BR 112022005995A BR 112022005995 A2 BR112022005995 A2 BR 112022005995A2
Authority
BR
Brazil
Prior art keywords
domain variants
domain
chain
same
light chain
Prior art date
Application number
BR112022005995A
Other languages
English (en)
Inventor
Arvind Sivasubramanian
Eric Krauland
Kevin Schutz
Michaela Helble
Paul Widboom
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of BR112022005995A2 publication Critical patent/BR112022005995A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N19/00—Methods or arrangements for coding, decoding, compressing or decompressing digital video signals
    • H04N19/10—Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using adaptive coding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Signal Processing (AREA)
  • Multimedia (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as. mesmas. variantes de domínio ch1 manipuladas para ligação preferencial a um domínio kappa cl ou a um domínio lambda cl, bem como polipeptídeos, por exemplo, cadeias pesadas de anticorpos ou anticorpos, compreendendo tais variantes de domínio ch1 manipuladas e composições farmacêuticas compreendendo tais variantes de domínio ch1 e/ou tais polipeptídeos e métodos para fazer e usar tais variantes de domínio ch1 são fornecidas. as variantes do domínio ch1 minimizam o emparelhamento incorreto de cadeia pesada-cadeia leve e promovem o emparelhamento cognato de cadeia pesada-cadeia leve, melhorando assim a geração de anticorpos multiespecíficos, por exemplo, biespecíficos. também são fornecidos métodos para fazer bibliotecas de variantes de domínio ch1 e métodos para identificar uma ou mais variantes de domínio ch1.
BR112022005995A 2019-09-30 2020-09-30 Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas BR112022005995A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962908367P 2019-09-30 2019-09-30
PCT/US2020/053482 WO2021067404A2 (en) 2019-09-30 2020-09-30 Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same

Publications (1)

Publication Number Publication Date
BR112022005995A2 true BR112022005995A2 (pt) 2022-06-21

Family

ID=75338609

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005995A BR112022005995A2 (pt) 2019-09-30 2020-09-30 Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas

Country Status (11)

Country Link
US (1) US20230265134A1 (pt)
EP (1) EP4021939A4 (pt)
JP (1) JP2022550172A (pt)
KR (1) KR20220107163A (pt)
CN (1) CN114846027A (pt)
AU (1) AU2020357944A1 (pt)
BR (1) BR112022005995A2 (pt)
CA (1) CA3152460A1 (pt)
IL (1) IL291728A (pt)
MX (1) MX2022003744A (pt)
WO (1) WO2021067404A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
US20230048743A1 (en) * 2021-07-12 2023-02-16 Genentech Inc. Structures for Reducing Antibody-Lipase Binding
US11873348B2 (en) * 2021-11-05 2024-01-16 Alligator Bioscience Ab Peptides
WO2023169559A1 (en) * 2022-03-11 2023-09-14 Elpiscience Biopharma , Ltd. Modified antibodies and uses thereof
WO2024061223A1 (zh) * 2022-09-20 2024-03-28 普米斯生物技术(珠海)有限公司 抗体及其在抗肿瘤中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561264A1 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
KR20150143458A (ko) * 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
EP2966085A1 (en) * 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
WO2016172485A2 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CN109476763B (zh) * 2016-07-19 2023-11-07 伊班绰斯有限责任公司 双特异性蛋白质及其制备方法

Also Published As

Publication number Publication date
AU2020357944A1 (en) 2022-03-31
MX2022003744A (es) 2022-07-21
WO2021067404A3 (en) 2021-05-14
CN114846027A (zh) 2022-08-02
IL291728A (en) 2022-05-01
EP4021939A2 (en) 2022-07-06
US20230265134A1 (en) 2023-08-24
KR20220107163A (ko) 2022-08-02
JP2022550172A (ja) 2022-11-30
EP4021939A4 (en) 2023-11-22
CA3152460A1 (en) 2021-04-08
WO2021067404A2 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
BR112022005995A2 (pt) Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
EA201990331A1 (ru) Мультиспецифические антигенсвязывающие белки и способы их применения
CO2019009432A2 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
CO2021003900A2 (es) Moléculas de unión a antígeno biespecíficas que comprenden el clon 212 anti-fap
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
BR112021021754A2 (pt) Cicloalquilas substituídas como moduladoras da via de estresse integrada
CL2008003779A1 (es) Anticuerpo bivalente bioespecifico que consta de las cadenas ligeras y pesadas de anticuerpos que se une a un primer y segundo antigeno, en el que los dominios constantes cl y ch1 y variables vl y vh, de las cadenas del anticuerpo para el segundo antigeno, se reemplazan entre si; metodo de producción; composición farmaceutica.
BR112017003236A2 (pt) anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
ECSP099032A (es) Composiciones y métodos para la modulación del desarrollo vascular
AR060871A1 (es) Union de polipeptidos con supercontigos optimizados
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
AR069775A1 (es) Anticuerpos bivalentes biespecificos
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CR11193A (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
UY30776A1 (es) Anticuerpos cd44
EA200970909A1 (ru) Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
AR076018A1 (es) Anticuerpos multiespecificos especialmente biespecificos
CY1118592T1 (el) Μεθοδοι για την αναστολη της δεσμευσης της ενδοσιαλινης σε προσδετες